Want to see TNYA full AI Analyst Report?
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.53 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$160.38M
Enterprise Value$47.77M
Total Cash (Recent Filing)$80.89M
Total Debt (Recent Filing)$10.12M
Price to Earnings (P/E)―
Beta2.79
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding216,998,870
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue212.30
Enterprise Value/Gross Profit146.53
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$10.33Price Target Upside676.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$10.21M
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityLow financial leverage and positive equity provide durable balance-sheet flexibility for a clinical-stage biotech. This reduces immediate insolvency risk, supports continued R&D spending or partnering negotiations, and gives management options (debt, partnerships, milestone deals) to fund trials without immediate commercial revenue.
Focused Genetic Medicines PipelineA concentrated pipeline targeting cardiovascular disease with gene and cell therapies aligns with a large, underserved market and favorable structural trends toward genetic medicines. Durable advantage: successful clinical outcomes could create high barriers to entry, long product lifecycles and royalty or product revenue streams if trials progress to approval.
Experienced Finance Leadership HireHiring a CFO with prior biotech finance and operational experience can materially improve long-term capital allocation, investor communication, and M&A or partnership execution. Strong finance leadership is durable: it can lower funding costs, optimize deal structures and better align resources to pivotal trials as the company scales development.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flows create a structural dependence on external financing to sustain operations and trials. Over the medium term this elevates dilution and execution risk, constrains strategic optionality, and increases pressure to secure partnerships or raise capital before reaching revenue-generating milestones.
No Durable Revenue Base; Large LossesMinimal revenue combined with deep, recurring losses means the company lacks self-sustaining cash generation. Until clinical programs translate into partnered milestones or approved products, the firm will remain loss-making, raising execution risk for advancing late-stage trials and limiting ability to internally fund commercialization.
Expanded Equity Plan Increases Dilution RiskBroadening the equity incentive pool and removing pre-set caps raises the probability of meaningful future share issuance for compensation or financing. While it aids recruitment/retention, structurally it increases potential dilution, reducing per-share upside and signaling reliance on equity as a likely funding mechanism during continued cash burn.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.53 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $160.38M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.002.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,998,870 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went up 7.342%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (676.94% Upside)
$10.33 (676.94% Upside)
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-80.56%
Trailing 12-Months
Asset Growth
-6.17%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$10.33
▲(676.94% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
23.34% Insiders
4.58% Mutual Funds
7.28% Other Institutional Investors
59.98% Public Companies and Individual Investors